Categories · Health/Science
· Lung Cancer
· Diabetes
|
Jump to full article: PR Newswire, 2008-04-09 Author: SOURCE Nektar Therapeutics
Intro: Nektar
Therapeutics (Nasdaq: NKTR) announced today that it has ceased all
negotiations with potential partners for its inhaled insulin programs as a
result of new data analysis from ongoing clinical trials conducted by
Pfizer Inc. An increase in the number of new cases of lung cancer was
observed in inhaled insulin patients as compared to the control group. All
new incidences of lung cancer were in patients that are former smokers.
Jump to full article » |